Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Download All
In this this dynamic program on the optimal treatment of patients with relapsed or refractory HER2-positive advanced breast cancer, renowned breast cancer experts review and discuss key clinical data and patient case studies and look ahead at promising agents that may soon change practice.
Adam M. Brufsky, MD, PhD
person default
Cristina Saura, MD, PhD

ClinicalThought

How confident are you in managing patients who experience interstitial lung disease while receiving trastuzumab deruxtecan?

Adam M. Brufsky, MD, PhD Released: September 10, 2020

Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with HER2-positive MBC.

person default Cristina Saura, MD, PhD Released: September 11, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue